The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders
Open accessAbstract
Medications to treat cognitive disorders are increasingly needed, yet researchers have had few successes in this challenging arena. Cognitive abilities in primates arise from highly evolved N-methyl-d-aspartate (NMDA) receptor circuits in layer III of the dorsolateral prefrontal cortex. These circuits have unique modulatory needs that can differ from the layer V neurons that predominate in rodents, but they offer multiple therapeutic targets. Cognitive improvement often requires low doses that enhance the pattern of information held in working memory, whereas higher doses can produce nonspecific changes that obscure information. Identifying appropriate doses for clinical trials may be helped by assessments in monkeys and by flexible, individualized dose designs. The use of guanfacine (Intuniv) for prefrontal cortical disorders was based on research in monkeys, supporting this approach. Coupling our knowledge of higher primate circuits with the powerful methods now available in drug design will help create effective treatments for cognitive disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Guanfacine, a specific α2-AR antagonist, has been used to treat cognitive disorders linked to PFC dysfunction 251.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [251]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Meeting of minds: the medial frontal cortex and social cognition
Amodio, D. M., & Frith, C. D. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1884 · Cited by 3,782 · cited 1×
“The rostral and dorsomedial aspects of the PFC also play important roles in social cognition, including so-called theory of mind, the ability to think about what another person must be thinking (19, 20).”
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693
Mnemonic coding of visual space in the monkey's dorsolateral prefrontal cortex
Funahashi, S., Bruce, C. J., & Goldman-Rakic, P. S. (1989) · Journal of Neurophysiology · doi:10.1152/jn.1989.61.2.331 · Cited by 2,685
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Ongur, D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.206 · Cited by 2,627
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Fuster, J. M. (1997) · Cited by 2,095
Flagged first, then by citations
Research works printed but not linked: 3
- Goldman-Rakic PS, 1987, Handbook of Physiology, The Nervous System, Higher Functions of the Brain, 373
- Robinson RG, 1985, Psychiatr. Dev., 3, 335
- 10.3389/fnana.2011.00029 · DOI · Paper page
Cited by
Sorted by citations
Yan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“Guanfacine, a speci fi c α 2-AR antagonist, has been used to treat cognitive disorders linked to PFC dysfunction [251].”
MethodRole of Prefrontal Persistent Activity in Working Memory
Riley, M. R., & Constantinidis, C. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00181 · Cited by 251
Single-cell spatial transcriptome reveals cell-type organization in the macaque cortex
Chen, A., Sun, Y., Lei, Y., Li, C., Liao, S., Meng, J., Bai, Y., Liu, Z., Liang, Z., Zhu, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.009 · Cited by 232
Self-citationKrystal, J. H., Anticevic, A., Yang, G., Dragoi, G., Driesen, N. R., Wang, X., & Murray, J. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.01.004 · Cited by 201
Feng, G., Jensen, F. E., Greely, H. T., Okano, H., Treue, S., Roberts, A., Fox, J. G., Caddick, S. J., Poo, M.-M., Newsome, W. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006515117 · Cited by 124
Metadata
- Authors
- Arnsten, A. F. T., & Wang, M.
- Affiliations
- Yale University (US)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2016-01-06
- Volume
- 56
- Issue
- 1
- Pages
- 339-360
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- PMC
- PMC4734124
- OpenAlex
- W2134555567
- Cited by
- 50
- References
- 138
- Citations by year
- 2024: 5 · 2023: 1 · 2021: 4 · 2020: 10 · 2019: 6 · 2018: 15 · 2017: 7 · 2016: 2
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (DP1AG047744, R01AG043430)
- National Institute of Mental Health (R01MH093354, R01MH100064)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- cognitive disorders, prefrontal cortex, NMDA receptor, dorsolateral prefrontal cortex, working memory, guanfacine, dose-response relationship, nonhuman primate model, drug development, cognitive enhancement
- MeSH terms
- Animals, Cognition, Cognition Disorders, Humans, Neurons, Prefrontal Cortex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
